Pregled bibliografske jedinice broj: 1197333
Impact of adalimumab on clinical outcomes, healthcare resource utilization and sick leave in ankylosing spondylitis patients in Central and Eastern Europe.
Impact of adalimumab on clinical outcomes, healthcare resource utilization and sick leave in ankylosing spondylitis patients in Central and Eastern Europe. // EULAR 2017
Madrid, Španjolska, 2017. str. 342-343 (poster, međunarodna recenzija, sažetak, znanstveni)
CROSBI ID: 1197333 Za ispravke kontaktirajte CROSBI podršku putem web obrasca
Naslov
Impact of adalimumab on clinical outcomes,
healthcare resource utilization and sick leave in
ankylosing spondylitis patients in Central and
Eastern Europe.
Autori
Opris-Belinski, D ; Erdes, S ; Grazio, Simeon ; Šenolt, L ; Hojnik, M ; Nagy, O ; Iosub, L ; Szanto, S
Vrsta, podvrsta i kategorija rada
Sažeci sa skupova, sažetak, znanstveni
Skup
EULAR 2017
Mjesto i datum
Madrid, Španjolska, 14.06.2017. - 17.06.2017
Vrsta sudjelovanja
Poster
Vrsta recenzije
Međunarodna recenzija
Ključne riječi
ankylosing spondylitis ; sick leave ; adalimumab
Sažetak
Treatment with adalimumab in routine clinical practice in 5 CEE countries resulted in clinically meaningful improvements in disease activity and physical function as well as reduced healthcare resource utilization and sick leaves.
Izvorni jezik
Engleski
Znanstvena područja
Kliničke medicinske znanosti, Biotehnologija u biomedicini (prirodno područje, biomedicina i zdravstvo, biotehničko područje)
